The CEO of Takis Luigi Aurisicchio, interviewed by Tagadà – La7, gave a brief demonstration on how our COVID-19 vaccine will be administered to patients by DNA-electroporation technology.
In addition, he explained what are the main differences of our candidate compared to the other vaccines currently in development. Our Covid-eVax is based on synthetic DNA only and is quick to produce, can be injected several times and modified over time to adapt it to virus mutations.
The full interview: